Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LENZ LENZ Therapeutics	$33.73 -2.4%	$30.30	$16.54 ▼ $38.93	$949.50M	0.42	199,394 shs	288,046 shs
NBTX Nanobiotix	$5.26 +0.8%	$4.55	$2.76 ▼ $6.00	$247.90M	0.41	15,529 shs	4,408 shs
NRIX Nurix Therapeutics	$11.21 -7.3%	$11.47	$8.18 ▼ $29.56	$857.01M	2.15	849,959 shs	782,724 shs
SANA Sana Biotechnology	$4.63 +4.0%	$2.78	$1.26 ▼ $7.30	$1.04B	1.86	3.93 million shs	5.02 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LENZ LENZ Therapeutics	0.00%	-2.77%	+12.66%	+39.90%	+57.25%
NBTX Nanobiotix	0.00%	-0.19%	+17.67%	+62.85%	-2.59%
NRIX Nurix Therapeutics	0.00%	-9.89%	-2.44%	+6.26%	-46.05%
SANA Sana Biotechnology	0.00%	+10.77%	+77.39%	+191.19%	-20.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LENZ LENZ Therapeutics	1.3363 of 5 stars	3.6	0.0	2.2	0.8	0.0
NBTX Nanobiotix	1.8825 of 5 stars	3.3	5.0	0.0	0.0	0.6
NRIX Nurix Therapeutics	2.5707 of 5 stars	4.4	1.0	3.1	0.8	0.0
SANA Sana Biotechnology	3.4466 of 5 stars	3.5	3.0	3.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LENZ LENZ Therapeutics	3.17	Buy	$46.60	38.16% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	52.09% Upside
NRIX Nurix Therapeutics	2.82	Moderate Buy	$29.31	161.49% Upside
SANA Sana Biotechnology	3.00	Buy	$9.17	97.98% Upside

Current Analyst Ratings Breakdown

Latest NBTX, NRIX, SANA, and LENZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
5/8/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.42 per share	N/A
NBTX Nanobiotix	$39.18M	6.33	N/A	N/A	($1.51) per share	-3.48
NRIX Nurix Therapeutics	$54.55M	15.71	N/A	N/A	$7.44 per share	1.51
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LENZ LENZ Therapeutics	-$49.77M	-$1.77	N/A	N/A	N/A	N/A	-23.74%	-22.65%	8/13/2025 (Estimated)
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/16/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	N/A
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)

Latest NBTX, NRIX, SANA, and LENZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.62	N/A	N/A	N/A	N/A	N/A
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LENZ LENZ Therapeutics	N/A	23.09	23.09
NBTX Nanobiotix	N/A	1.04	1.04
NRIX Nurix Therapeutics	N/A	6.82	6.82
SANA Sana Biotechnology	N/A	3.40	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LENZ LENZ Therapeutics	54.32%
NBTX Nanobiotix	38.81%
NRIX Nurix Therapeutics	N/A
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
LENZ LENZ Therapeutics	6.90%
NBTX Nanobiotix	3.45%
NRIX Nurix Therapeutics	7.40%
SANA Sana Biotechnology	31.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LENZ LENZ Therapeutics	110	28.15 million	26.20 million	N/A
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
SANA Sana Biotechnology	380	225.48 million	155.35 million	Optionable

NBTX, NRIX, SANA, and LENZ Headlines

Recent News About These Companies

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Rating of "Buy" from Analysts

July 17, 2025 | marketbeat.com

Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan Stanley

July 11, 2025 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Shares Gap Up - Here's Why

July 9, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 14.1% - Still a Buy?

July 8, 2025 | marketbeat.com

Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting

July 4, 2025 | msn.com

Sana Biotechnology (NASDAQ:SANA) Coverage Initiated by Analysts at Morgan Stanley

July 3, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 7.6% - What's Next?

July 2, 2025 | marketbeat.com

Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results

June 29, 2025 | insidermonkey.com

Sana Biotechnology’s SWOT analysis: promising cell therapy stock faces crowded market - Investing.com

June 26, 2025 | investing.com

Sana Biotechnology (SANA) Receives a Buy from Citizens JMP

June 26, 2025 | theglobeandmail.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 4.5% - Time to Sell?

June 25, 2025 | marketbeat.com

BofA Remains Bullish on Sana Biotechnology (SANA)

June 24, 2025 | insidermonkey.com

Sana Biotechnology (NASDAQ:SANA) Given Market Outperform Rating at JMP Securities

June 24, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 17.2% - Should You Buy?

June 23, 2025 | marketbeat.com

Sana Biotechnology stock soars after positive diabetes treatment results

June 23, 2025 | investing.com

Two Biotech Stocks Poised For Big Moves On Monday

June 23, 2025 | benzinga.com

Sana Biotechnology Shares Climb on Positive Diabetes Study Results

June 23, 2025 | marketwatch.com

Sana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 Diabetes

June 23, 2025 | quiverquant.comQ

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

June 23, 2025 | globenewswire.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Moderate Buy" from Analysts

June 22, 2025 | marketbeat.com

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

June 9, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX, NRIX, SANA, and LENZ Company Descriptions

LENZ Therapeutics NASDAQ:LENZ

$33.73 -0.84 (-2.43%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$33.78 +0.05 (+0.15%)

As of 07/18/2025 07:52 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Nanobiotix NASDAQ:NBTX

$5.26 +0.04 (+0.77%)

As of 07/18/2025 04:00 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Nurix Therapeutics NASDAQ:NRIX

$11.21 -0.88 (-7.28%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.50 +0.29 (+2.59%)

As of 07/18/2025 07:44 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Sana Biotechnology NASDAQ:SANA

$4.63 +0.18 (+4.04%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.59 -0.04 (-0.86%)

As of 07/18/2025 07:57 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time